Morbidity and Mortality in Hemodialysis Patients with and without Erythropoietin Treatment: A Controlled Study

Abstract Hemodialysis patients present more morbidity and mortality risk in coronavirus disease 2019. In patients who may develop severe symptoms the process called “viral sepsis” seems to be a crucial mechanism. In those cases, the hemodialysis procedure provides an excellent tool to explore the benefit of some extracorporeal therapies. We reported the outcome of 4 hemodialysis patients with severe COVID-19 treated with Seraph®100 hemoperfusion device. Three of four cases presented a good clinical response after hemoperfusion. In conclusion, the treatment with Seraph®100 device may be a simultaneous treatment to improve the hemodialysis patients with severe SARS-CoV-2.

Download Full-text

Serum ferritin is a marker of morbidity and mortality in hemodialysis patients

American Journal of Kidney Diseases ◽

10.1053/ajkd.2001.22433 ◽

2001 ◽

Vol 37 (3) ◽

pp. 564-572 ◽

Cited By ~ 86

Author(s):

Kamyar Kalantar-Zadeh ◽

Burl R. Don ◽

Rudolph A. Rodriguez ◽

Michael H. Humphreys

Keyword(s):

Serum Ferritin ◽

Hemodialysis Patients ◽

Morbidity And Mortality

Download Full-text

Effect of dietary sodium restriction on body water, blood pressure, and inflammation in hemodialysis patients: a prospective randomized controlled study

International Urology and Nephrology ◽

10.1007/s11255-013-0382-6 ◽

2013 ◽

Vol 46 (1) ◽

pp. 91-97 ◽

Cited By ~ 30

Author(s):

Lidiane Silva Rodrigues Telini ◽

Gabriela de Carvalho Beduschi ◽

Jacqueline Costa Teixeira Caramori ◽

João Henrique Castro ◽

Luis Cuadrado Martin ◽

...

Keyword(s):

Blood Pressure ◽

Hemodialysis Patients ◽

Body Water ◽

Dietary Sodium ◽

Randomized Controlled Study ◽

Controlled Study ◽

Sodium Restriction ◽

Randomized Controlled ◽

Dietary Sodium Restriction

Download Full-text

Neonatal Infection and Premature Rupture of Membranes

PEDIATRICS ◽

10.1542/peds.33.3.467a ◽

1964 ◽

Vol 33 (3) ◽

pp. 467-467

Author(s):

KIT G. JOHNSON

Keyword(s):

Group Versus ◽

Neonatal Infection ◽

Morbidity And Mortality ◽

Controlled Study ◽

Premature Rupture Of Membranes ◽

Premature Rupture ◽

Clinical Sepsis ◽

Amniotic Membranes

As the article by Pryles, et al. entitled "A Controlled Study of the Influence on the Newborn of Prolonged Premature Rupture of the Amniotic Membranes and/or Infection in the Mother," Pediatrics, Vol. 31, pp. 608-622, has not yet received comment in your journal, perhaps it is not too late to ask the authors to fill three hiati which I felt existed in their presentation of this excellent study. As antibiotics apparently were used (according to Table X) in some infants prior to the diagnosis of clinical sepsis, what were the comparative morbidity and mortality results in this group versus the group in which treatment was deferred until the diagnosis of clinical sepsis could be made?

Download Full-text

Atrial Fibrillation and Morbidity and Mortality in a Cohort of Long-term Hemodialysis Patients

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2007.10.034 ◽

2008 ◽

Vol 51 (2) ◽

pp. 255-262 ◽

Cited By ~ 140

Author(s):

Simonetta Genovesi ◽

Antonio Vincenti ◽

Emanuela Rossi ◽

Daniela Pogliani ◽

Irene Acquistapace ◽

...

Keyword(s):

Atrial Fibrillation ◽

Hemodialysis Patients ◽

Morbidity And Mortality

Download Full-text

THE EFFECT OF MONTHLY GAMMA-GLOBULIN ADMINISTRATION ON MORBIDITY AND MORTALITY FROM INFECTION IN PREMATURE INFANTS DURING THE FIRST YEAR OF LIFE

PEDIATRICS ◽

10.1542/peds.32.1.4 ◽

1963 ◽

Vol 32 (1) ◽

pp. 4-9 ◽

Cited By ~ 1

Author(s):

Jules Amer ◽

Esther Ott ◽

Frank A. Ibbott ◽

Donough O'Brien ◽

C. Henry Kempe

Keyword(s):

Premature Infants ◽

Gamma Globulin ◽

Repeated Administration ◽

Morbidity And Mortality ◽

Controlled Study ◽

First Year ◽

Double Blind ◽

First Year Of Life

A double-blind controlled study to determine the effect on infections of repeated administration of large doses of gamma-globulin to premature infants revealed that significantly more of these infants had no infections and fewer had mild infections during the first year of life. The data also suggests that gamma-globulin afforded some amelioration of serious but nonfatal infections. Deaths from infection showed a similar trend in favor of the gamma-globulin group, but this difference on its own was not significant.

Download Full-text

SP439EXERCISE TRAINING AND DOPAMINE AGONISTS IN HEMODIALYSIS PATIENTS WITH RESTLESS LEGS SYNDROME. A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED STUDY

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfv194.03 ◽

2015 ◽

Vol 30 (suppl_3) ◽

pp. iii523-iii524

Author(s):

Giorgos Sakkas ◽

Christoforos Giannaki ◽

Christina Karatzaferi ◽

Georgios M. Hadjigeorgiou ◽

Ioannis Stefanidis

Keyword(s):

Restless Legs Syndrome ◽

Dopamine Agonists ◽

Hemodialysis Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Restless Legs

Download Full-text

Prophylactic Melatonin for Delirium in Intensive Care (Pro-MEDIC): study protocol for a randomised controlled trial

Trials ◽

10.1186/s13063-016-1751-0 ◽

2017 ◽

Vol 18 (1) ◽

Cited By ~ 23

Author(s):

F. Eduardo Martinez ◽

Matthew Anstey ◽

Andrew Ford ◽

Brigit Roberts ◽

Miranda Hardie ◽

...

Keyword(s):

Intensive Care ◽

Critically Ill ◽

Controlled Trial ◽

Study Drug ◽

Assessment Method ◽

Trial Registration ◽

Morbidity And Mortality ◽

Controlled Study ◽

Clinical Trial Registry ◽

Icu Discharge

Abstract Background Delirium is an acute state of brain dysfunction characterised by fluctuating inattention and cognitive disturbances, usually due to illness. It occurs commonly in the intensive care unit (ICU), and it is associated with greater morbidity and mortality. It is likely that disturbances of sleep and of the day-night cycle play a significant role. Melatonin is a naturally occurring, safe and cheap hormone that can be administered to improve sleep. The main aim of this trial will be to determine whether prophylactic melatonin administered to critically ill adults, when compared with placebo, decreases the rate of delirium. Methods This trial will be a multi-centre, randomised, placebo-controlled study conducted in closed ICUs in Australia. Our aim is to enrol 850 adult patients with an expected ICU length of stay (LOS) of 72 h or more. Eligible patients for whom there is consent will be randomised to receive melatonin 4 mg enterally or placebo in a 1:1 ratio according to a computer-generated randomisation list, stratified by site. The study drug will be indistinguishable from placebo. Patients, doctors, nurses, investigators and statisticians will be blinded. Melatonin or placebo will be administered once per day at 21:00 until ICU discharge or 14 days after enrolment, whichever occurs first. Trained staff will assess patients twice daily to determine the presence or absence of delirium using the Confusion Assessment Method for the ICU score. Data will also be collected on demographics, the overall prevalence of delirium, duration and severity of delirium, sleep quality, participation in physiotherapy sessions, ICU and hospital LOS, morbidity and mortality, and healthcare costs. A subgroup of 100 patients will undergo polysomnographic testing to further evaluate the quality of sleep. Discussion Delirium is a significant issue in ICU because of its frequency and associated poorer outcomes. This trial will be the largest evaluation of melatonin as a prophylactic agent to prevent delirium in the critically ill population. This study will also provide one of the largest series of polysomnographic testing done in ICU. Trial registration Australian New Zealand Clinical Trial Registry (ANZCTR) number: ACTRN12616000436471. Registered on 20 December 2015.

Download Full-text